Evidence map›Paper›PMID 40999135›Full record

ReviewWorld journal of microbiology & biotechnology2025

Recent advances in metabolic engineering of Escherichia coli for riboflavin biosynthesis.

Shuang Liu, Dongchang Sun

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Development of Bacillus subtilis cell factories for nutraceuticals production.World journal of microbiology & biotechnology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shuang LiuCollege of Biotechnology and Bioengineering, Zhejiang University of Technology, 310014, Hangzhou, Zhejiang, China.
Dongchang SunCollege of Biotechnology and Bioengineering, Zhejiang University of Technology, 310014, Hangzhou, Zhejiang, China. sundch@zjut.edu.cn.

Funding

National Natural Science Foundation of China 32170083 and 31670084Scientific Research Starting Foundation of Zhejiang University of Technology 202214105000229
6 · The paper itself

Abstract

Escherichia coli has emerged as a promising microbial platform for industrial riboflavin (RF) biosynthesis, enabled by systematic metabolic engineering of its well-characterized genetic system. This minireview synthesizes key strategies for enhancing RF production, focusing on: (i) Precursor optimization through reinforced pentose phosphate pathway flux (elevating ribulose-5-phosphate) and deregulated purine biosynthesis (boosting GTP availability); (ii) Pathway engineering via rib operon overexpression coupled with feedback inhibition relief through ribF modulation and FMN riboswitch deletion; (iii) Competitive flux minimization by redirecting carbon from acetate formation and catabolic side-reactions; and (iv) Cellular robustness enhancement through NADPH/ATP cofactor balancing and stress tolerance engineering. Complementary bioreactor parameter control including defined media formulations, temperature profiling, and dynamic pH/dissolved oxygen regulation has proven critical for translating laboratory-scale genetic improvements to high-titer production. Recent advances in CRISPR-based genome editing, multi-omics-guided pathway optimization, and antibiotic-free plasmid stabilization demonstrate E. coli's growing viability as a sustainable RF cell factory, with future progress hinging on integrated systems metabolic engineering approaches.

Indexed as

Escherichia coliMetabolic EngineeringRiboflavinBioreactorsBiosynthetic PathwaysGene EditingMetabolic Networks and PathwaysPentose Phosphate PathwayRiboflavinEscherichia coliMetabolic engineeringRiboflavin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.